Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Blue Chip Shares
These top ASX 200 stocks could rise 25% to 60%
Share Market News
These ASX 200 blue chip shares could rise 25% to 40%
Healthcare Shares
This Cochlear-backed ASX aspirant will be targeting an epilepsy market worth north of $1 billion
Blue Chip Shares
3 amazing ASX 200 blue chip shares that could be strong buys
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
5 things to watch on the ASX 200 on Thursday
Healthcare Shares
Four healthcare stocks Wilsons Advisory says are worth a look
Broker Notes
Pro Medicus, Cochlear, REA: Are the 3 most expensive ASX 200 shares still a buy?
How to invest
The easy way to build a $30,000 a year passive income
How to invest
How to build generational wealth with ASX shares
Blue Chip Shares
5 blue chip ASX 200 shares to buy in October and hold for 10 years
Broker Notes
A top broker thinks this ASX 200 healthcare share could rise 25%
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
